MedTrace Logo

Volasertib Combined With Induction Chemotherapy in Acute Myeloid Leukemia

NCT02905994 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2018-05-04

No results posted yet for this study

Summary

The study intervention involved in this study is the addition of a dose of volasertib as a part of the initial chemotherapy regimen for AML.

The trial will involve a combination of the following drugs:

* Volasertib (the study drug)
* Idarubicin
* Cytarabine

Conditions

Interventions

DRUG

Volasertib

Polo-Like Kinase Inhibitor

DRUG

Cytarabine

Standard chemotherapy at dosage and schedule for 7+3 induction

DRUG

Idarubicin

Standard chemotherapy at dosage and schedule for 7+3 induction

PROCEDURE

Bone Marrow Biopsy

Bone marrow biopsy assessments scheduled during induction to assess response

Sponsors & Collaborators

Principal Investigators

  • Amir T Fathi, MD, PhD · Massachusetts General Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-09-30
Primary Completion
2017-02-28
Completion
2017-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02905994 on ClinicalTrials.gov